A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Trial Profile

A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Pelareorep (Primary) ; Carboplatin; Paclitaxel
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 22 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 May 2013 Planned End Date changed from 1 Jan 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 19 Jul 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top